Objectives: To describe the interstitial fluid (ISF) and plasma pharmacokinetics of meropenem in patients on continuous venovenous haemodiafiltration (CVVHDF).
Introduction
Sepsis is the most common cause of acute kidney injury (AKI) in critically ill patients. 1 The incidence of AKI can vary depending on the criteria used to define its occurrence. According to the RIFLE criteria, up to two-thirds of patients in ICUs will develop AKI, 2 and for those requiring continuous renal replacement therapy (CRRT) mortality rates between 40% and 60% have been described. 2, 3 There are many patient and CRRT factors that can influence drug dosing requirements for individual patients.
Continuous venovenous haemodiafiltration (CVVHDF) is a commonly prescribed mode of CRRT, which eliminates a drug via diffusive and convective processes.
The importance of early and appropriate antibiotic therapy for minimizing mortality has been well described in critically ill patients. 4, 5 To maximize the antibiotic efficacy of carbapenems, the unbound (or free) antibiotic concentration should be maintained above the MIC for at least 40% of the dosing interval. 6 Although antibiotic pharmacokinetics are frequently reported for plasma, such details for the infection site are often lacking. The # The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2015; 70: 528 -533 doi:10.1093/jac/dku413 Advance Access publication 21 October 2014 pathophysiological changes that occur during sepsis can result in perfusion and fluid volume changes in the interstitial fluid (ISF), resulting in subtherapeutic antibiotic concentrations in the target tissues in which the infection is residing. 7 -9 Microdialysis is a minimally invasive sampling technique that allows the measurement of unbound drug concentrations in the ISF, which is considered the target site of treatment for most infections. 10 Previous studies have demonstrated that patients with sepsis and septic shock can have significantly lower b-lactam antibiotic concentrations in their ISF compared with healthy volunteers. 7, 11, 12 Our previous data, as well as those from other authors, have also shown that the extent of ISF penetration of b-lactams can be quite different from the corresponding plasma concentrations in patients with sepsis and septic shock. 7 -9 We are unaware of any previous pharmacokinetic studies measuring the ISF concentrations of meropenem during CRRT.
This study aimed to describe the plasma and ISF pharmacokinetics of meropenem in critically ill patients with AKI receiving CVVHDF. We also aimed to compare data on the extent of ISF penetration with data previously reported for other b-lactam antibiotics in other critically ill patient groups.
Patients and methods

Study design
This was a prospective pharmacokinetic study conducted in a 30 bed intensive care unit in a tertiary referral hospital. Ethics approval for the study was obtained from the Royal Brisbane and Women's Hospital Human Research Ethics Committee (HREC/08/QRBW/7) and the Medical Research Ethics Committee of The University of Queensland (2009000667). Written informed consent was obtained from each patient's legally authorized representative. Critically ill patients receiving CRRT were eligible for enrolment. Pharmacokinetic sampling to describe meropenem concentrations was undertaken on two occasions (defined as Profiles A and B) between Days 2 and 5 of antibiotic therapy.
CRRT settings
CRRT was performed using the CVVHDF mode with an Aquarius CRRT machine. Vascular access was through a double-lumen catheter in the internal jugular or femoral vein. The haemofilter was a hollow-fibre high flux AN69 Nephral ST 200 (Gambro Lundia AB, Lund, Sweden) polyacrylonitrile filter with a surface area of 1.05 m 2 . The dialysis and replacement fluid used was either Haemofiltration Solution (HF1) (Gambro) or lactatefree Hemosol BO (Gambro).
Drug dosing
Meropenem was administered as a 500 mg dose every 8 h as an intravenous bolus over 3 min through a central venous catheter.
Blood and CRRT effluent sample collection
Intensive blood samples were collected both pre-and post-filter (3 mL each) at 0, 3 min, 10 min, 20 min, 30 min, 1 h, 2 h, 3 h and 8 h. Filtrate/ dialysate samples were collected at 1 h, 2 h and 3 h in order to calculate the saturation coefficient at these timepoints. Samples collected were stored on ice; the blood samples were centrifuged at 3000 rpm for 10 min and the plasma and filtrate/dialysate samples were stored at 2808C until analysis.
Microdialysis
The principles of microdialysis have previously been described. 13 Briefly, microdialysis is used to sample molecules from extracellular fluid using the process of diffusion across a semipermeable membrane. Once the probe has been implanted in the tissue, analytes diffuse across the membrane from the ISF into the perfusate and may be sampled and analysed. We used a microdialysis catheter with a 20 kDa molecular weight cut-off, outer diameter of 0.6 mm and membrane length of 30 mm (CMA 60; Dipylon Medical, Solna, Sweden). The catheter was inserted into the upper arm in all but one of the patients, this patient having the microdialysis catheter inserted into the upper thigh. The microdialysis catheter was constantly perfused with cefalotin (10 mg/L; as a calibrator) in 0.9% sodium chloride at a flow rate of 1.6 mL/min. Microdialysate samples were intensively collected at 15 min intervals for the first hour and then every 30 min for the remainder of the 8 h dosing interval. The microdialysate samples (in microvials) and microdialysis perfusate samples were also stored at 2808C until analysis.
The recovery of meropenem in the microdialysate solution was calculated based on the loss of the calibrator (cefalotin) across the microdialysis membrane into the ISF based on the retrodialysis by calibrator method:
where C in is 10 mg/L cefalotin (perfusate) and C out is the measured cefalotin concentration in the microdialysate.
Bioanalysis
Meropenem and cefalotin concentrations were measured using a validated HPLC assay method. The concentration range of the assay was as follows: plasma, 0.2 -50 mg/L meropenem; dialysate/filtrate, 1 -200 mg/L meropenem; and microdialysate, 0.1-50 mg/L meropenem and 0.1-50 mg/L cefalotin. Intrabatch precision and accuracy was within 6% at three levels of quality control (high, medium and low).
Data analysis
Pharmacokinetic analysis was conducted using a non-compartmental approach. The methods used to calculate the common pharmacokinetic parameters such as k el and elimination t 1/2 have previously been described. 15 The other equations used in the pharmacokinetic analyses are discussed below. Results were reported as median (IQR). A MannWhitney U-test was used to compare the results between sampling occasions as appropriate using SPSS version 22.0 (SPSS Inc., Chicago, USA).
Total clearance (CL total ) was calculated based on the following equation:
where AUC 0 -1 is the area under the concentration -time curve between time 0 and infinity calculated using the linear trapezoidal rule between 0 and 8 h, with extrapolation from 8 h to infinity calculated assuming a loglinear decline. V was determined according to the following equation:
where C 0 is the concentration in the plasma at time zero calculated by back-extrapolation from the concentration versus time data obtained between 2 and 8h. In our reported results, the following equation was used to calculate CVVHDF clearance (CL CVVHDF ):
Meropenem pharmacokinetics during CVVHDF 529 JAC where C pre is the pre-filter plasma concentration, C post is the post-filter plasma concentration, Q plasma is the blood flow corrected for haematocrit and Q uf is the pure ultrafiltration flow. The CL CVVHDF for each patient was calculated by taking the average of the CL CVVHDF values calculated at the available timepoints.
The following equation was used to calculate the saturation coefficient:
The saturation coefficient for each patient was calculated by taking the average of the saturation coefficient values calculated at the available timepoints.
The non-CRRT clearance (CL other ) was calculated based on the following equation:
The extent of penetration into the ISF was calculated according to the following equation:
where AUC is the area under the concentration -time curve during the dosing interval calculated using the linear trapezoidal rule. Based on our pre-filter plasma concentration data, the percentage of time above the MIC (%T .MIC ) was calculated using the following equation:
where t 1/2 is the plasma elimination half-life.
Results
A total of 384 samples (161 blood, 178 microdialysate and 45 filtrate/dialysate or dialysis effluent samples) were collected from five patients (three men and two women) over two dosing intervals. The clinical, demographic and CRRT details of the patients are summarized in Table 1 . The dialysate flow rate was 1 L/h in all patients and the post-filter replacement fluid rate was 2 L/h in all but one patient (Subject 3), who received replacement fluid at a rate of 1 L/h. The combined filtrate/dialysate or effluent flow rate ranged between 2.2 and 3.3 L/h or 18 and 52 mL/kg/h in this study. Four out of the five patients underwent sampling of blood, filtrate/dialysate and microdialysate on two occasions, at least 24 h apart. The CRRT settings were similar on the two occasions (see Table 1 ). The pharmacokinetic parameter estimates for each of the two separate occasions are reported as Profile A and Profile B in Table 2 . The median number of doses prior to Profile A was 6 (range 3-12) doses. The concentration -time profiles of meropenem in plasma and ISF are presented in Figure 1 . The extent of penetration of meropenem into the ISF was between 60% and 70% and appeared to increase from the first to the second occasion of sampling, although the difference was not statistically significant (P .0.05).
The calculated %T .MIC in plasma and ISF for this sample are reported in Table 3 HCT, haematocrit; F, female; M, male; NA, not available; VAP, ventilator-associated pneumonia. Anuria was defined as the absence of urine output or a urine output ,50 mL/day.
Oliguria was defined as a low urine output (,0.5 mL/kg/h) for 6 consecutive hours.
The calculation of the TPP score (as published by Zeitlinger et al.
24
) takes into consideration the following parameters: oxygen saturation, serum lactate and dose of noradrenaline administered per time unit (mg/kg/min).
Varghese et al.
Discussion
This study extends previous studies examining the ISF distribution of b-lactam antibiotics in critically ill patients and is to our knowledge the first study of meropenem during CRRT. 7 -9,11,12,17,18 Our results show that where these CVVHDF settings are used, adequate ISF and plasma concentrations of meropenem are achieved where the infection is mediated by susceptible bacteria, using a dose of 500 mg intravenously every 8 h. Different antibiotics are likely to have different ISF penetration characteristics due to physicochemical differences. Meropenem penetration has been studied, using the microdialysis technique, for various different tissues or sites of infection including CSF, peritoneal fluid, lung tissue and subcutaneous tissue. 9,19 -21 The mean ISF penetration for meropenem reported in the literature has ranged from 0.41 in lung tissue 21 up to 0.79 in peritoneal fluid. 20 In this study of patients on CRRT, the median penetration into the subcutaneous tissue across both occasions of sampling was 0.6-0.7.
The ratio of AUC for the ISF to AUC for the plasma (AUC ISF / AUC plasma ratio) increased between the two sampling occasions (not statistically significant), possibly indicating gradually accumulating concentrations in the ISF with time. Our previously published data 9 on meropenem penetration into the ISF of the subcutaneous tissue of patients with sepsis (bolus versus continuous infusion) reported an AUC ISF /AUC plasma of 0.74 in the bolus dosing group after patients had received a 1.5 g first dose on Day 1 of meropenem therapy. This higher AUC ISF /AUC plasma ratio may support the use of a loading dose to rapidly achieve adequate plasma and ISF concentrations on the first day of meropenem treatment in patients with sepsis. The pathophysiological changes that occur during sepsis can lead to fluid shifts from the intravascular space to the interstitial space, resulting in an increased V for hydrophilic antibiotics such as b-lactams, 22, 23 resulting in decreased plasma and ISF concentrations of these drugs. Further, the fluid retention common in AKI may also affect these concentrations. Hence, a loading dose may be advantageous to rapidly achieve target drug concentrations.
Data on the plasma and ISF pharmacokinetics of b-lactam antibiotics in other critically ill patients have previously been reported, although such data remain limited. 7 -9,11,12,17,18 The first study highlighting the potential importance of an impaired ISF penetration of b-lactams was by Joukhadar et al. 7 In this study, ISF concentrations of piperacillin in patients with septic shock were 5 -10 times lower than plasma concentrations. This landmark study raised concerns that an impaired target site penetration of b-lactams may be responsible for treatment failure in critically ill patients. Our previous data 8 on piperacillin found that subcutaneous tissue ISF concentrations were 1 -5 times lower than plasma concentrations. The higher subcutaneous tissue ISF concentration of piperacillin that we observed compared with that reported by Joukhadar et al. 7 was considered to be due to the greater severity of illness in the patients in the latter study. Based on these previous microdialysis studies, 7, 8 we are led to conclude that septic shock and vasopressor administration, with the associated reduced peripheral perfusion, is likely to be the main cause of reduced ISF concentrations of b-lactam antibiotics, although a comparison across studies should only be cautiously performed as differences in microdialysis settings may affect the results observed.
Four of the five patients in our study were taking vasopressors; however, due to small patient numbers, we were unable to make any meaningful comparison of the ISF penetration ratio in patients who were on and not on vasopressors. As shown in Meropenem pharmacokinetics during CVVHDF 531 JAC Table 1 , the patients on vasopressors had higher tissue penetration prediction (TPP) scores, calculated according to the published TPP score criteria, which take into consideration oxygen saturation, serum lactate and dose of noradrenaline administered per unit time (mg/kg/min). 24 Apart from meropenem and piperacillin, data on ISF penetration in muscle or subcutaneous tissue in critically ill patients is only available for two other b-lactam antibiotics: cefpirome and imipenem. Cefpirome in patients with sepsis was associated with an AUC ISF /AUC plasma of 0.63 and 0.43 for muscle and subcutaneous ISF, respectively. 11, 12 For imipenem, contrasting ISF penetration data exist between the two studies in patients with sepsis. 17, 18 Measuring the muscle distribution of imipenem, a study by Tegeder et al. 18 reported a mean AUC ISF /AUC plasma of 0.1 compared with an AUC ISF /AUC plasma of 1 reported in a study by Dahyot et al. 17 The patient characteristics in the two studies did not appear to differ significantly and there may therefore have been some methodological differences between the studies that resulted in the differing results.
b-Lactams, being hydrophilic antibiotics, generally have a V that is consistent with extracellular water. In healthy volunteers, the V of meropenem is reported to be 0.26 L/kg, 25 but in critically ill patients a V of up to 0.47 L/kg 26 has been reported, mainly due to the pathophysiological changes discussed above. The median V in this study was 0.35 L/kg and 0.33 L/kg for Profiles A and B, respectively. Krueger et al., 27 in their study of patients on CVVHDF, report a mean V of 0.26 L/kg. Robatel et al., 28 however, report a higher V with a mean of 0.47 L/kg in their patients on CVVHDF, which may possibly be due to the increased severity of illness in their patient cohort, who were mainly patients with cardiogenic or septic shock.
Only the unbound fraction of a drug in the systemic circulation can be cleared across the haemofilter membrane. Therefore, the saturation coefficient, an important determinant of CL CVVHDF , is also closely related to the unbound fraction of the drug. The CL CVVHDF results in our study (median 2.9 L/h for Profile A) were higher than the CL CVVHDF of 1.6 L/h reported in the study by Robatel et al. 28 The main differences between the CVVHDF settings in the study by Robatel et al. 28 was the use of pre-filter dilution (i.e. the administration of replacement fluid pre-filter) and a lower total effluent range (1.3-2.3 L/h), compared with post-filter dilution and a higher total effluent range (2.2-3.3 L/h) in our study, which may explain the higher CL CVVHDF observed using our CVVHDF settings. These findings reinforce that differences in CRRT settings need to be carefully considered when comparing CL CVVHDF results and dosing recommendations from different pharmacokinetic studies.
An important limitation of this study is the small number of patients enrolled. However, even with the small patient numbers, the rich data obtained from the plasma, microdialysis and filtrate/ dialysate samples enabled us to adequately describe the plasma and ISF pharmacokinetics in this patient population on CVVHDF and compare our results with those of previous studies. Further, the data were not widely distributed for our patients, suggesting that additional data collection would be unlikely to change our findings. Another limitation is that the ISF concentrations measured in the subcutaneous tissue were not from the actual site of infection in our patients as this site is extremely difficult to sample. We measured subcutaneous ISF concentrations since these are likely to be more instructive of infection site ISF concentrations than are plasma concentrations.
Conclusions
Our results show that meropenem has 60% -70% penetration into the ISF in critically ill patients with AKI who are receiving CVVHDF. For the settings of CVVHDF used in this study, 500 mg of meropenem administered every 8 h achieves adequate infection site (ISF) and plasma concentrations of meropenem when treating infections mediated by susceptible and intermediately susceptible bacteria. Higher doses may be required when targeting more resistant organisms and also with the use of different CRRT settings that may increase the CL CVVHDF of meropenem.
